LifeScience Clinical & Diagnostic

OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon

OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device comp...

 July 28, 2026 | News

Roche Secures US FDA Clearance for PCR Test Detecting Bacterial Vaginosis and Candida Vaginitis

The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated wi...

 July 28, 2026 | News

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

 July 27, 2026 | News

Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma

Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...

 July 27, 2026 | News

GHIT Fund Invests JPY 140M to Accelerate Portable Rapid Diagnostic System for Ebola

The Global Health Innovative Technology (GHIT) Fund announced an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portab...

 July 24, 2026 | News

Menarini Asia-Pacific, Pharmacosmos Partner to Expand Cosela® Access Across APAC

Menarini Asia-Pacific announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) acr...

 July 23, 2026 | News

Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs

Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...

 July 22, 2026 | News

China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer

SystImmune Inc.  announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...

 July 21, 2026 | News

Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...

 July 20, 2026 | News

Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe

• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...

 July 17, 2026 | News

Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment

First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sy...

 July 17, 2026 | News

Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...

 July 17, 2026 | News

Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

 July 16, 2026 | News

Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...

 July 15, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close